Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting Progression--ZAP-70 in CLL

Terry J Hamblin1

  • 1Department of Immunohaematology, University of Southampton, Southampton, United Kingdom.

The New England Journal of Medicine
|August 27, 2004
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2012
Same author

Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia.

Leukemia research·2011
Same author

The TCL1 mouse as a model for chronic lymphocytic leukemia.

Leukemia research·2009
Same author

Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men?

Nature clinical practice. Oncology·2009
Same author

Non-hemic autoimmunity in CLL.

Leukemia research·2008
Same author

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Blood·2008
Same journal

Advances in Multiple Sclerosis.

The New England journal of medicine·2026
Same journal

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

The New England journal of medicine·2026
Same journal

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

The New England journal of medicine·2026
Same journal

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.

The New England journal of medicine·2026
See all related articles